Skip to navigation Skip to content

Hidradenitis suppurativa (HS) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051119

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised biological medicines for patients with moderate to severe hidradenitis suppurativa (HS).

HS and listing dates

Moderate to severe HS is a chronic skin condition featuring lumps in places such as the armpits or groin.

Listing dates:

  • adalimumab - 1 July 2017
  • secukinumab - 1 June 2024

See Written Authority Required Drugs for more details.

Treatment specifics

A break in treatment cycles is measured:

  • from the date of last approval for PBS-subsidised biological medicine treatment in the most recent cycle
  • to the date of the first application for initial treatment with a biological medicine under the new treatment cycle

There is no limit to the number of treatment cycles.

See Treatment breaks and failures for details.

Enquiries

Transfer enquiries about prescription arrangements to Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • FAQs from Service Officers
  • the PBS schedule
  • Services Australia websites link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority requests

Written Authority Required Drugs